Literature DB >> 10874473

Effects of Bcl-2 and Bcl-XL protein levels on chemoresistance of hepatoblastoma HepG2 cell line.

D Luo1, S C Cheng, H Xie, Y Xie.   

Abstract

The ratio between apoptotic promoters and repressors in the Bcl-2 family determines the chemosensitivity of cells to apoptotic stimuli. This study examines the chemoresistance of a transfected human hepatoblastoma HepG2 cell-line during Taxol and Doxorubicin application. Sense bcl-2, and anti-sense bcl-XL gene fragments were separately inserted into HepG2 cells via stable transfection. The expression profile of the Bcl-2 family proteins was determined by Western blot analysis. Chemosensitivity of the transfected cells was measured by Trypan blue exclusion assay and XTT reduction assay during drug application. In the absence of Bax protein, HepG2 cells with elevated Bcl-2 protein levels did not exhibit any significant increase in chemosensitivity towards the drugs. Transfected cells with reduced Bcl-XL levels became more sensitive to the drugs, and a significant difference in IC50 values was observed. The chemosensitivity of HepG2 cells to Taxol and Doxorubicin was not affected by Bcl-2 levels, while reduction of Bcl-XL levels rendered the cells more sensitive to the drugs. This suggests that the Bcl-2 protein alone could not protect HepG2 cells from drug-induced apoptosis, and that the Bcl-XL protein may be a target for gene therapy in hepatoblastoma treatment.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10874473

Source DB:  PubMed          Journal:  Biochem Cell Biol        ISSN: 0829-8211            Impact factor:   3.626


  14 in total

1.  Effect of short hairpin RNA of Bcl-xL gene on biological behaviors of HepG-2 cells.

Authors:  Duan Mengxi; Yuan Hong; Wang Nan; Li Shijun; Jiang Yanmei
Journal:  Med Oncol       Date:  2011-04-29       Impact factor: 3.064

2.  Tyrosine-phosphorylated caveolin-1 (Tyr-14) increases sensitivity to paclitaxel by inhibiting BCL2 and BCLxL proteins via c-Jun N-terminal kinase (JNK).

Authors:  Ayesha N Shajahan; Zachary C Dobbin; F Edward Hickman; Sivanesan Dakshanamurthy; Robert Clarke
Journal:  J Biol Chem       Date:  2012-03-20       Impact factor: 5.157

3.  A survey on herbal management of hepatocellular carcinoma.

Authors:  Nabil Mohie Abdel-Hamid; Maiiada Hasan Nazmy; Ahmed Wahid Mahmoud; Michael Atef Fawzy; Marco Youssof
Journal:  World J Hepatol       Date:  2011-07-27

4.  Bcl-XL, but not Bcl-2, can protect human B-lymphoma cell lines from parthenolide-induced apoptosis.

Authors:  Alan T Yeo; John A Porco; Thomas D Gilmore
Journal:  Cancer Lett       Date:  2011-12-06       Impact factor: 8.679

Review 5.  Clinical Pharmacokinetics and Pharmacodynamics of Transarterial Chemoembolization and Targeted Therapies in Hepatocellular Carcinoma.

Authors:  Anne Hulin; Jeanick Stocco; Mohamed Bouattour
Journal:  Clin Pharmacokinet       Date:  2019-08       Impact factor: 6.447

6.  Partial Beclin 1 silencing aggravates doxorubicin- and Fas-induced apoptosis in HepG2 cells.

Authors:  Fanny Daniel; Agnès Legrand; Dominique Pessayre; Nathalie Vadrot; Véronique Descatoire; Dominique Bernuau
Journal:  World J Gastroenterol       Date:  2006-05-14       Impact factor: 5.742

Review 7.  Fast, hungry and unstable: finding the Achilles' heel of small-cell lung cancer.

Authors:  Christine L Hann; Charles M Rudin
Journal:  Trends Mol Med       Date:  2007-02-26       Impact factor: 11.951

8.  The Proto-oncogene PKCι regulates the alternative splicing of Bcl-x pre-mRNA.

Authors:  Jacqueline C Shultz; Ngoc Vu; Michael D Shultz; Mba-Uzoma U Mba; Brian A Shapiro; Charles E Chalfant
Journal:  Mol Cancer Res       Date:  2012-04-20       Impact factor: 5.852

9.  Multiplexed, high-throughput analysis of 3D microtissue suspensions.

Authors:  Alice A Chen; Gregory H Underhill; Sangeeta N Bhatia
Journal:  Integr Biol (Camb)       Date:  2010-09-01       Impact factor: 2.192

10.  Involvement of Cox-2 in the metastatic potential of chemotherapy-resistant breast cancer cells.

Authors:  Ju-Hee Kang; Ki-Hoon Song; Kyung-Chae Jeong; Sunshin Kim; Changsun Choi; Chang Hoon Lee; Seung Hyun Oh
Journal:  BMC Cancer       Date:  2011-08-04       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.